ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $5.9M.
Where they traded
Last open-market purchase: September 18, 2025 — 1.0 years ago, by Gline Matthew .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Fitzgerald Meghan 2 fills | Director | Sell 10b5-1 | 5,112 | $39.74 | $203.2K | 36,508 −12.3% of holding | |
| Epperly Melissa B, 2 fills | Director | Sell 10b5-1 | 4,938 | $39.74 | $196.2K | 10,500 −32% of holding | |
| Fitzgerald Meghan | Director | Sell 10b5-1 | 20,000 | $39.90 | $798.0K | 42,963 −31.8% of holding | |
| Venker Eric 2 fills | President & Immunovant CEO | Sell 10b5-1 | 200,000 | $35.77 | $7.2M | 1,632,972 −10.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.